U.S. stock index futures jumped on Friday, with Wall Street looking to deliver its best week since the election in November ...

Medicare seeks to negotiate prices on 15 drugs, including Novo Nordisk's (NVO) GLP-1 weight-loss drugs Ozempic and Wegovy, in ...

GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along ...

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. Vandana Singh Novo Nordisk's Higher ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For ...

NVO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Additionally, the company could be a top pick for growth investors. NVO has a Growth Style Score of A, forecasting year-over-year ...

Investors in Novo-Nordisk AS (Symbol: NVO) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVO ...

Short interest in Novo Nordisk AS (NYSE:NVO) increased during the last reporting period, rising from 4.70M to 8.30M. This put 0.26% of the company's publicly available shares short. Short interest ...